{"id":1347,"date":"2025-08-03T01:23:35","date_gmt":"2025-08-03T01:23:35","guid":{"rendered":"http:\/\/www.youtubexyoutube.com\/?p=1347"},"modified":"2025-08-08T13:50:49","modified_gmt":"2025-08-08T13:50:49","slug":"russian-lab-unveils-cancer-vaccine-release-target","status":"publish","type":"post","link":"http:\/\/www.youtubexyoutube.com\/index.php\/2025\/08\/03\/russian-lab-unveils-cancer-vaccine-release-target\/","title":{"rendered":"Russian lab unveils cancer vaccine release target"},"content":{"rendered":"

Personalized treatment could begin \u201cwithin months,\u201d according to the Gamaleya Center\u2019s director<\/strong><\/p>\n

<\/strong> Russia\u2019s first patients could begin receiving a newly developed cancer vaccine within the next few months, Alexander Gintsburg, director of the Gamaleya Research Institute of Epidemiology and Microbiology, has announced. The breakthrough drug is a personalized, AI-assisted, mRNA-based vaccine designed to target malignant tumors using the patient\u2019s own genetic data.<\/p>\n

Speaking to RIA Novosti on Saturday, Gintsburg confirmed that the experimental phase of administering the treatment will start \u201cin the coming months,\u201d<\/em> in cooperation with two leading oncology institutions \u2013 the Hertsen Research Institute and the Blokhin Cancer Center in Moscow. According to Gintsburg, the Gamaleya Center is responsible for producing the vaccine, while patient trials will be conducted by the partnering clinics.<\/p>\n

\u201cIn accordance with the plan approved by the Health Ministry, we are preparing to begin experimental treatment using the cancer vaccine based on neoantigens in a group of melanoma patients,\u201d<\/em> Gintsburg said. He emphasized that the drug is \u201centirely personalized,\u201d<\/em> created specifically for each patient using their unique tumor data, and cannot be used for anyone else.<\/p>\n

\n Read more<\/strong><\/span><\/p>\n

\n \"RT\"
\u2018Cancer will evolve but can be defeated in its current form\u2019 \u2013 head of Gamaleya research institute<\/a><\/figcaption><\/figure>\n<\/blockquote>\n

The development of the vaccine began in mid-2022 and applies messenger RNA (mRNA) technology. The treatment works by training the patient\u2019s immune system to recognize tumor-specific proteins (antigens) and destroy malignant cells throughout the body using cytotoxic lymphocytes.<\/p>\n

Due to its individualized nature, the cancer vaccine is subject to a unique regulatory framework adopted by the Russian government earlier this year. \u201cThis is a fundamentally different process from the registration of standard drugs,\u201d<\/em> Gintsburg explained, noting that the team is working closely with health authorities to move forward under the new guidelines.<\/p>\n

The vaccine, initially designed for melanoma patients, has already shown promising results in animal trials and limited tests on human patients. Gintsburg previously stated that the entire production process \u2013 from analyzing the tumor to creating a tailored vaccine \u2013 can be completed in about a week with the help of artificial intelligence.<\/p>\n

\n Read more<\/strong><\/span><\/p>\n

\n \"Oracle
Oracle boss pledges individual AI MRNA cancer vaccines<\/a><\/figcaption><\/figure>\n<\/blockquote>\n

The Gamaleya Center, which created the world\u2019s first registered Covid-19 vaccine, Sputnik V, is also currently developing models for treating other oncological diseases, including pancreatic, kidney, and non-small-cell lung cancer \u2013 the most frequently diagnosed cancer with the highest mortality rate and one that is notoriously difficult to treat.<\/p>\n

Russia\u2019s Health Ministry estimates there are around 4 million cancer patients in the country, with roughly 625,000 new cases diagnosed annually. The cancer vaccine project could become a major milestone in Russia\u2019s public health strategy if it proves safe and effective during the upcoming trial phase. The innovation has attracted international interest, with Gintsburg confirming that several foreign medical institutions have reached out to express a desire to collaborate.<\/p>\n","protected":false},"excerpt":{"rendered":"

Personalized treatment could begin \u201cwithin months,\u201d according to the Gamaleya Center\u2019s director Russia\u2019s first patients could begin receiving a newly […]<\/p>\n","protected":false},"author":1,"featured_media":1349,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[11],"tags":[],"_links":{"self":[{"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/posts\/1347"}],"collection":[{"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/comments?post=1347"}],"version-history":[{"count":2,"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/posts\/1347\/revisions"}],"predecessor-version":[{"id":1352,"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/posts\/1347\/revisions\/1352"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/media\/1349"}],"wp:attachment":[{"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/media?parent=1347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/categories?post=1347"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.youtubexyoutube.com\/index.php\/wp-json\/wp\/v2\/tags?post=1347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}